MET and small-cell lung cancer

Francesco Gelsomino, Giulio Rossi, Marcello Tiseo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.

Original languageEnglish
Pages (from-to)2100-2115
Number of pages16
JournalCancers
Volume6
Issue number4
DOIs
Publication statusPublished - Oct 13 2014

Fingerprint

Small Cell Lung Carcinoma
Molecular Biology
Neoplasms
Radiation
Recurrence
Lung
Therapeutics
Genes

Keywords

  • c-MET
  • c-MET signaling pathway
  • Mutations
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gelsomino, F., Rossi, G., & Tiseo, M. (2014). MET and small-cell lung cancer. Cancers, 6(4), 2100-2115. https://doi.org/10.3390/cancers6042100

MET and small-cell lung cancer. / Gelsomino, Francesco; Rossi, Giulio; Tiseo, Marcello.

In: Cancers, Vol. 6, No. 4, 13.10.2014, p. 2100-2115.

Research output: Contribution to journalArticle

Gelsomino, F, Rossi, G & Tiseo, M 2014, 'MET and small-cell lung cancer', Cancers, vol. 6, no. 4, pp. 2100-2115. https://doi.org/10.3390/cancers6042100
Gelsomino F, Rossi G, Tiseo M. MET and small-cell lung cancer. Cancers. 2014 Oct 13;6(4):2100-2115. https://doi.org/10.3390/cancers6042100
Gelsomino, Francesco ; Rossi, Giulio ; Tiseo, Marcello. / MET and small-cell lung cancer. In: Cancers. 2014 ; Vol. 6, No. 4. pp. 2100-2115.
@article{404da4fe6d4148d2b02682e011c0208e,
title = "MET and small-cell lung cancer",
abstract = "Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.",
keywords = "c-MET, c-MET signaling pathway, Mutations, Small-cell lung cancer",
author = "Francesco Gelsomino and Giulio Rossi and Marcello Tiseo",
year = "2014",
month = "10",
day = "13",
doi = "10.3390/cancers6042100",
language = "English",
volume = "6",
pages = "2100--2115",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - MET and small-cell lung cancer

AU - Gelsomino, Francesco

AU - Rossi, Giulio

AU - Tiseo, Marcello

PY - 2014/10/13

Y1 - 2014/10/13

N2 - Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.

AB - Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.

KW - c-MET

KW - c-MET signaling pathway

KW - Mutations

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84919771755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919771755&partnerID=8YFLogxK

U2 - 10.3390/cancers6042100

DO - 10.3390/cancers6042100

M3 - Article

AN - SCOPUS:84919771755

VL - 6

SP - 2100

EP - 2115

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

ER -